BerGenBio ASA (OSL: BGBIO)

Market Cap	426.05M
Revenue (ttm)	521.00K
Net Income (ttm)	-155.41M
Shares Out	39.09M
EPS (ttm)	-5.37
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	128,415
Open	11.30
Previous Close	11.08
Day's Range	10.85 - 11.30
52-Week Range	10.10 - 35.80
Beta	1.62
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2024

About BerGenBio ASA

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory diseases in Norway. The company’s lead clinical asset is the Bemcentinib (BGB016), an inhibitor of AXL receptor tyrosine kinase (AXL), which is in phase 1b/2a clinical trial to treat non-small cell lung cancer; and (BGBC008), which is in phase 2 clinical trial to treat second-line non-small cell lung cancer (2L NSCLC). It develops Bemcentinib, which is in preclinical trial to treat acute...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 16
• Stock Exchange: Oslo Børs
• Ticker Symbol: BGBIO

Financial Performance

In 2023, BerGenBio ASA's revenue was 354,000, a decrease of -9.00% compared to the previous year's 389,000. Losses were -190.40 million, -36.98% less than in 2022.